linjc16/ctgov huggingface dataset:
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Study Overview
=================
Brief Summary
-----------------
Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior therapies. The study will take place globally at multiple study centers. Subjects will be enrolled to receive ganetespib one time per week for three weeks followed by a rest week; and will repeat this schedule until the cancer gets worse or the subject is unable to tolerate ganetespib. The primary goal of the study is to determine how ganetespib is tolerated and how active it is in ALK positive NSCLC.

Official Title
-----------------
A Single Arm, Phase 2 Study of Ganetespib in Subjects With Advanced Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: Ganetespib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females aged 18 years or older Pathological confirmation of advanced NSCLC Evidence of a translocation or an inversion event involving the ALK gene locus ECOG Performance Status 0 or 1 Exclusion Criteria: Prior therapy with ALK-targeted agents Prior treatment with Hsp90 inhibitor Known EGFR activating mutation Presence of active or untreated central nervous system (CNS) metastases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ganetespib<br>Ganetespib IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval | Drug: Ganetespib<br>* Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of Response |  | 1 year | 
| Disease Control Rate |  | 6 weeks and 12 weeks | 
| Adverse events |  | 1 year | 
| Progression Free Survival |  | From the date of study drug start until the date of first documented progression or date of death from any cause, whichever comes frist, assessed up to 3 years | 
| Overall Survival |  | 1 year |
Mirror Therapy and Hand Rehabilitation

Study Overview
=================
Brief Summary
-----------------
Objective: The purpose of this study is to determine effects of mirror therapy in restoring hand function in patients with flexor lag following orthopedic injuries. Methods: In a prospective randomized controlled trial, 22 patients with Flexor Lag will be measured. Intervention group will receive mirror therapy, 30-minute a day, 5 days a week for 3-week, as well, half an hour conventional rehabilitation after each mirror therapy session. Patients in the control group will receive the same treatment program, but instead of mirror, they will directly observe the affected hand. Outcome measures including Total Active Motion (TAM), and Disabilities of Arm, Shoulder and Hand (DASH) questionnaire will be administered before and after the treatment period and 3 weeks after the final treatment session.

Official Title
-----------------
Mirror Therapy in Patients With Hand Orthopedic Disorders

Conditions
-----------------
Hand Fractures

Intervention / Treatment
-----------------
* Other: Mirror therapy
* Other: Classical rehabilitation techniques


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hand orthopedic Injuries more active range of motion than passive range of motion Exclusion Criteria: crush injuries hand deformities not treated fractures and tendon ruptures complex regional pain syndrome psychiatric problems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mirror Therapy Group<br>Mirror Therapy Group | Other: Mirror therapy<br>* mirror therapy<br>|
| Sham Comparator: Control Group<br>Control Group receive classical rehabilitation techniques including splinting, tendon gliding, ... | Other: Classical rehabilitation techniques<br>* splinting, tendon gliding, active range of motion, activities of daliy living<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Active Motion | Sum of Range of Motion in Metacarpophalangeal, Proximal Interphalangeal and Distal Interphalangeal Joints. | 6 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disabilities of the Shoulder, Arm, hand |  | 6 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hand Flexor tendon Injuries, hand Extensor Tendon Injuries, Hand Joint Dislocations and subluxation
Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract

Study Overview
=================
Brief Summary
-----------------
Fecal calprotectin is a very sensitive non-invasive inflammation marker in the detection of inflammatory bowel disease and, to a lesser degree, has also proven to be useful in adenomatous polyps, neoplasias, and infectious gastroenteritis. Elevated calprotectin levels can also be found in patients with lesion only in the upper gastrointestinal tract. However, the diagnostic value of calprotectin has never been tested in this setting. The aim of the study is therefore to determine the diagnostic value of fecal calprotectin in patients with diseases of the upper gastrointestinal tract.

Official Title
-----------------
Value of Fecal Calprotectin in Upper Gastrointestinal Disease

Conditions
-----------------
Peptic Esophagitis, Peptic Ulcer, Functional Dyspepsia, Irritable Bowel Syndrome, Inflammatory Bowel Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients referred for upper gastrointestinal endoscopy for any reason Older than 18 years Exclusion Criteria: Patients who are not able to provide informed consent Patients who are not able to provide a stool sample

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse

Study Overview
=================
Brief Summary
-----------------
Obtaining data on efficacy (e.g. complete ST-segment resolution) depending on the time of treatment initiation and safety of prehospital and early hospital thrombolysis with Metalyse® in a real life setting outside clinical trials.

Official Title
-----------------
Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Prehospital or Early Inhospital (Emergency Department) Thrombolysis With Metalyse ®

Conditions
-----------------
Myocardial Infarction

Intervention / Treatment
-----------------
* Drug: Metalyse weight-adjusted


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Male and female patient with suspected myocardial infarction, e.g. during transportation to the hospital by ambulance. No patient younger than 18 years. Possibility of obtaining relevant information concerning indication or contraindication of thrombolysis in each patient Typical chest pain with a duration of more than 30 minutes Definite infarction signs in a 12-lead-ECG with ST-elevation > 0.1 millivolt (mV) in > 2 leads or recent left bundle branch block with typical clinical signs Symptom onset <= 6 hours Exclusion criteria: Patients older than 75 years (exception: patients appear much younger) Low body weight No persons under 18 contraindications according to summary of product characteristics (SPC) for Metalyse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Metalyse<br>Metalyse weight-adjusted | Drug: Metalyse weight-adjusted<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete ST-segment resolution |  | up to 30 days | 
| Pain relief | yes/no question | 90 min, 120 min, up to 30 days after treatment initiation | 
| Change in creatine kinase (CK) |  | up to 24 hours | 
| Change in creatine kinase-MB (CK-MB) |  | up to 24 hours | 
| Change in troponin |  | up to 24 hours |
Lung Volume Perception and Impact of a Cognitive Task on Ventilation in Hypermobile Ehlers-Danlos Syndrome.

Study Overview
=================
Brief Summary
-----------------
Patients with hypermobile Ehlers-Danlos syndrome have respiratory and proprioceptive disorders. The aim of this study is to explore whether there is an alteration in lung volume perception in patients with hEDS compared to healthy subjects, and whether a cognitive task can influence ventilation control differently in subjects with hEDS than in healthy subjects.

Official Title
-----------------
Lung Volume Perception and Impact of a Cognitive Task on Ventilation in Healthy Subjects and Subjects With Hypermobile Ehlers-Danlos Syndrome.

Conditions
-----------------
Hypermobile Ehlers-Danlos Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (common): More than 18 years old Understanding French Inclusion Criteria (hEDS Patients): hEDS diagnosis Inclusion Criteria (healthy subjects): Age (±5 years), Gender and BMI (±2.5kg/m²) matching Exclusion Criteria (common): Pregnancy Exclusion Criteria (hEDS Patients): Respiratory comorbidity independent of hEDS Previous participation in a rehabilitation programme at the clinic Exclusion Criteria (healthy subjects): Known respiratory or proprioceptive pathology Hypermobility (evaluated with the Beighton score)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients<br>Hypermobile Ehlers-Danlos patients (n=21) | |
| Healthy subjects<br>Healthy subjects recruited from the clinic's staff (n=21) Age, Gender and BMI matched with hEDS patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of lung volume perception | The perception of lung volume is assessed using a device comprising a flow meter, an electronic acquisition card and an LCD screen. Subjects will be given 3 trials to train to perceive a target lung volume and then 3 trials without feedback to reproduce that target lung volume. The mean of the absolute deviations from the target volumes in percent is used as the primary outcome. | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Minute ventilation with or without cognitive task | The minute ventilation will be calculated over 1 minute without cognitive task and then over 1 minute with cognitive task (trail making test part B). | Baseline | 
| Respiratory rate variability | The time interval between each inspiratory peak will be recorded and will allow the calculation of the standard deviation and the root mean square with and without the cognitive task. | Baseline |
Knowledge Attitudes, Beliefs, and Practices Regarding HIV in Populations Living on the Maroni River

Study Overview
=================
Brief Summary
-----------------
The HIV epidemic flared from 0 to over 1% prevalence in a decade on the Maroni river which lies between French Guiana and Surinameaim of the study is to determine the knowledge, attitudes, behaviours, and practices on HIV in the population living along the French bank of the Maroni border. Descriptive statistics are computed from the tabulation of answers to a structured questionnaire. Multivariate logistic models were computed to determine predictors of key outcomes. These data will help taylor prevention intervention in this very particular area.

Conditions
-----------------
HIV

Intervention / Treatment
-----------------
* Other: observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult living on the maroni river Exclusion Criteria: refusal to participate
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: observational|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| knowledge attitudes, beliefs, and practices regarding HIV and sexually transmitted diseases | a structured questionnaire was used.. it was administered face to face with usually 5 possible responses. Scores were established using similar questions exploring related areas of HIV. | when the interview was conducted |
Medline NE Pad Adhesion Testing

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to determine the neutral electrode 21pad adhesion to the skin in accordance with international standard IEC 60601-2-2 section 201.15.101.7. A neutral electrode is placed on the body of patients undergoing surgery that involves the use of electric current, to protect them from the harmful effects of the electricity.

Detailed Description
-----------------
Two neutral electrodes will be applied to the front of your thighs. The study staff will set up and attach a pulley system to the neutral electrodes. The purpose of the pulley system is to apply a force pulling the neutral electrode away from your body. The force will be applied for 10 minutes on each neutral electrode in one direction, and then for another 10 minutes in a second direction. Site staff will mark any areas of separation and the neutral electrodes will be removed.

Official Title
-----------------
Medline NE Pad Adhesion Testing

Conditions
-----------------
Adhesion of the Neutral Electrode 21pad

Intervention / Treatment
-----------------
* Device: Medline NE Grounding Pad


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants must be willing to comply with all study procedures Participants must be willing to shave, or to have shaved, the sites where the neutral electrodes will be placed. Exclusion Criteria: The participant has any skin conditions (e.g. eczema, sensitivities, allergies to adhesives, sunburn, etc.) at the application sites that might be adversely affected by the application of an adhesive pad. The participant is pregnant or breastfeeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Subjects<br>Subjects must be 18 years old or over, willing to shave or have shaved the sites where the neutral electrodes will be placed. Subjects also must not be pregnant, breastfeeding, have skin conditions (such as eczema, sensitivities, allergies to adhesives, sunburn). | Device: Medline NE Grounding Pad<br>* Split Universal Grounding Pads<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NE adhesive area separation | To determine the percent of adhesion pad pull test that had no more than 5% of the NE adhesive area separated. | One month |
Inspiratory Muscle Training in Patients With Autonomic Neuropathic

Study Overview
=================
Brief Summary
-----------------
This study describes a controlled randomized clinical trial to evaluate the effect of inspiratory muscle training in patients with diabetic autonomic neuropathy.

Detailed Description
-----------------
The diabetic autonomic neuropathy (NAD) is a common complication of diabetes mellitus (DM), both of the type 1 diabetes mellitus (DM1) as of the type 2 diabetes mellitus (DM2). The results of this study, would help to reveal the degree of commitment generated by NAD in respiratory muscle strength, can also enable the development of a new therapeutic approach, such non-pharmacological (respiratory muscle training), with a view to improve the respiratory muscle strength and alleviate the autonomic dysfunction in these patients.

Official Title
-----------------
Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial

Conditions
-----------------
Diabetes Mellitus, Diabetic Autonomic Neuropathy

Intervention / Treatment
-----------------
* Other: Inspiratory muscle training (IMT)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetic autonomic neuropathy Age between 36 and 70 years old and signed in informed consent form Exclusion Criteria: Presence of congestive heart failure Chronic obstructive pulmonary disease (FEV1 < 70% and/or FEV1%< 80 Class II or III obesity (body mass index > 35)

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inspiratory muscle strength |  | eight | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variability of heart rate |  | eight | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes Mellitus, Autonomic Neuropathy, Inspiratory Muscle training
fMRI in Blood Phobia Syncope

Study Overview
=================
Brief Summary
-----------------
We plan to study patient who faint in response to the sight of blood and compare them to healthy subjects who do not. We are going to use a special type of MRI scan (functional MRI) to determine if there are differences in brain activation in response to seeing bloody or gory pictures that occur before the fainting occurs.

Detailed Description
-----------------
Another aim of the study is to determine whether or not differences in personality traits among people with blood phobia is associated with differences in BOLD signal responses during fMRI.

Official Title
-----------------
Neuroimaging in Blood Phobia Syncope

Conditions
-----------------
Syncope, Blood Injury Phobia, Autonomic Dysfunction

Intervention / Treatment
-----------------
* Procedure: fMRI Scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-30 years of age 1. History of at least one syncopal episode upon exposure to viewing blood (Case Group) Negative urine pregnancy test on study day Exclusion Criteria: Vasoactive medications (within 2 weeks of study day) antihypertensives beta blockers vasoconstrictors Psychotropic medications (within 4 weeks of study day) History of psychostimulant or opiate use History of alcohol, benzodiazepine or cannabis abuse or dependence

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 2<br>Healthy control subjects (who do not faint at the sight of blood) | Procedure: fMRI Scan<br>* Subjects will undergo a functional MRI scan of the head lasting  45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.<br>|
| 1<br>People who faint at sight of blood | Procedure: fMRI Scan<br>* Subjects will undergo a functional MRI scan of the head lasting  45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fMRI BOLD signal |  | Immediate | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Injection Symptoms Scale |  | Single visit | 
| Disgust Scale (Revised) |  | Single Visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
syncope, faint, blood, blood injury phobia, phobia